Abstract

BackgroundPulmonary embolism (PE) is a life-threatening condition associated with ~10% of deaths of hospitalized patients. Machine learning algorithms (MLAs) which predict the onset of pulmonary embolism (PE) could enable earlier treatment and improve patient outcomes. However, the extent to which they generalize to broader patient populations impacts their clinical utility. ObjectiveTo conduct the first large-scale external validation of a machine learning–based PE prediction model which uses EHR data from the first three hours of a patient's hospital stay to predict the occurrence of PE within the next 10 days of the inpatient stay. MethodsThis retrospective study included approximately two million adult hospital admissions across 44 medical institutions in the US from 2011 to 2017. Demographics, vital signs, and lab tests from adult inpatients at 12 institutions (n = 331,268; 3.3% PE positive) were used for training an XGBoost model. External validation of the model was conducted on patient populations from each of 32 medical institutions (total n = 1,660,715; 3.7% PE positive) without retraining. Model performance was assessed using the area under the receiver operating characteristic curve (AUROC). Backward elimination regression was used to identify correlations between characteristics of the external validation sets and AUROC. ResultsThe model performed well (AUROC = 0.87) on the 20% hold-out subset of the training set. Despite demographic differences between the 32 external validation populations (percent PE positive: min = 1.54%, max = 6.47%), without retraining, the model had excellent discrimination, with a mean AUROC of 0.88 (min = 0.79, max = 0.93). Fixing sensitivity at 0.80, the model had a mean specificity of 0.85 (min = 0.64, max = 0.93). Backward elimination regression identified a negative association (β = −0.015, p < 0.001) between the percentage of PE positive encounters and AUROC. ConclusionsA PE prediction model performed remarkably well across 32 different external patient populations without retraining and despite significant differences in demographic characteristics, demonstrating its generalizability and potential as a clinical decision support tool to aid PE detection and improve patient outcomes in a clinical setting.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.